Overview of the Essential Drugs Segment in the Russian Pharmaceutical Market Based on the Results of 2017

According to the IQVIA data, in 2017 the Russian pharmaceutical market of EDL maintained its positive dynamics both by volume (+5%) and in the national currency (+9%). According to Federal Law of the Russian Federation No. 61-FZ "On drugs circulation" dated 12.04.2010 (as amended and suppl...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical sciences and research 2018-10, Vol.10 (10), p.2454-2456
Main Authors: Denisova, M N, Sudakova, A I, Glazkova, I U, Litvinova, T M, Smyslova, O A
Format: Article
Language:English
Subjects:
Acids
Analgesics
Audits
Blood substitutes
Budgets
Chloride
Nonsteroidal anti-inflammatory drugs
Pharmaceuticals
Prices
Sodium
Trends
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:According to the IQVIA data, in 2017 the Russian pharmaceutical market of EDL maintained its positive dynamics both by volume (+5%) and in the national currency (+9%). According to Federal Law of the Russian Federation No. 61-FZ "On drugs circulation" dated 12.04.2010 (as amended and supplemented, effective date 01.01.2017), the EDL is the list of drugs for medical use, which is annually approved by the Government of the Russian Federation and ensures priority health needs in the prevention and treatment of diseases, including the dominants in the Russian morbidity patterns (http://www.consultant.ru/document/cons_doc_law_99350/) [1]. According to the results of 2017, the share of drugs produced local manufacturer in the EDL segment was 33% by value. The new EDL adopted for 2018 included 60 new drugs, which creates the prerequisites to continue these processes. [...]in the medium term, taking into account these trends, the market will maintain a certain balance of forces, although the share of the Russian companies will continue to grow.
ISSN:0975-1459